Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2021-12-02 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于股东股份解除质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement from Betta Pharmaceuticals Co., Ltd. regarding the release of pledged shares by a shareholder. It details the number of shares released from pledge, the shareholder involved, and cumulative pledge status. The document is short (1433 characters) and focuses on share pledge status changes, which is a capital structure related update. It is not a full financial report, earnings release, or management discussion. It is not a voting result or board change announcement. The content fits best under Share Issue/Capital Change (SHA) as it relates to changes in share pledges, which affect capital structure.
2021-12-02 Chinese
关于贝伐珠单抗注射液（MIL60）获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration certificate from the National Medical Products Administration for a specific pharmaceutical product (MIL60). It includes details about the drug, regulatory approval, and potential impact on the company. The document is short (1181 characters) and serves as an official announcement of a regulatory milestone rather than a financial report or detailed presentation. It does not contain financial statements, management discussion, or detailed investor information. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-11-29 Chinese
关于BPI-442096片药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about the acceptance of a clinical trial application by the National Medical Products Administration (国家药品监督管理局). It details the clinical trial drug, its research background, and the regulatory acceptance notice. The document is short (1273 characters) and serves as an official announcement of regulatory acceptance rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types defined in the filing categories. Therefore, it best fits the category of a Regulatory Filing (RNS), which is a fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-11-18 Chinese
关于BPI-371153胶囊药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about the acceptance of a clinical trial application by the National Medical Products Administration (国家药品监督管理局). It details the clinical trial application for a new drug, BPI-371153, and provides information about the drug and the regulatory acceptance. The document is short (1022 characters) and serves as an official announcement of a regulatory event rather than a financial report or detailed filing. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2021-11-15 Chinese
2021年第三季度报告
Regulatory Filings
2021-10-27 Chinese
2021年第三季度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (407 characters) indicating that the company's 2021 third quarter report has been approved by the board and is available on a public disclosure website. It does not contain the actual financial data or the full report itself, but rather informs investors where to find the full quarterly report. According to the 'MENU VS MEAL' rule, such a brief notice that a report is published and available elsewhere should be classified as a Report Publication Announcement (RPA), not as the Interim/Quarterly Report (IR) itself.
2021-10-27 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.